Get all your news in one place.
100's of premium titles.
One app.
Start reading
Evening Standard
Evening Standard
Business
Oscar Williams-Grut

Private equity group Cinven hit with third fine for NHS price gouging

The price of migraine drug prochlorperazine rose 700% in four years

(Picture: PA Archive)

Private equity group Cinven has been hit with a third fine linked to price gouging on drugs sold to the NHS.

The Competition and Markets Authority today fined four drug companies a collective £35 million, with part of the fines passed on to the owners of one business. Cinven will share a £15.5 million fine due to its historic ownership of drug distributor Focus.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.